Trial · NCT07909317
Influence of Transcranial Electrical Stimulation on Arm and Hand Function After Cervical Spinal Cord Injury
NCT07909317, Not applicable, Not yet recruiting, Shepherd Center, Atlanta GA
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Influence of Transcranial Electrical Stimulation on Arm and Hand Function After Cervical Spinal Cord Injury. Trials, record NCT07909317. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909317
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Influence of Transcranial Electrical Stimulation on Arm and Hand Function After Cervical Spinal Cord Injury
- NCT number
- NCT07909317
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Shepherd Center, Atlanta GA
- Conditions
- Spinal Cord Injury
- Interventions
transcranial direct current stimulation (tDCS) + FTP, transcranial pulsed current stimulation (tPCS) + FTP, transcranial random noise stimulation (tRNS) + FTP, sham transcranial electrical stimulation (tES) + FTP
- First posted
- 2026-11-02
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in brain activity | Twice during each of the four testing & intervention sessions through study completion, an average of two weeks. | Electroencephalography (EEG) event-related potential (ERP) amplitude will be recorded in the left parietofrontal network during performance of a modified serial reaction time task (mSRTT). |
| Primary | Change in brain connectivity | Twice during each of the four testing & intervention sessions through study completion, an average of two weeks. | Electroencephalography (EEG) alpha band parietofrontal connectivity will be recorded under two conditions: 1) resting state and 2) during performance of a modified serial reaction time task (mSRTT). |
| Secondary | Change in upper extremity (UE) function | Twice during each of the four testing & intervention sessions through study completion, an average of two weeks. | Function will be measured in the right UE using the Graded Redefined Assessment of Strength Sensibility and Prehension version 2 (GRASSP v2) quantitative prehension subtest. Participants will complete four tasks: pouring water from a bottle to a cup, moving nine pegs from one side of a board to the other, inserting a key into a lock and rotating, and fastening four nuts onto screws. Each task will be scored on a 0-5 scale (0: task cannot be conducted at all - 5: task conducted without difficulty using the expected grasp pattern) and timed (maximum of 75 seconds will be allowed per task). The number of drops during each task will also be recorded. The total score, time and number of drops for all four tasks will then be calculated. The maximum score is 20 with higher scores denoting better UE function. |
| Secondary | Change in upper extremity (UE) strength | Twice during each of the four testing & intervention sessions through study completion, an average of two weeks. | Strength will be measured in the right UE using key pinch force. The participant will be positioned with the shoulder in neutral, elbow flexed at approximately 90º, and forearm and wrist in neutral. Force will be quantified with an electronic pinchmeter positioned between the middle phalanx of the index finger and thumb pad. The participant will be given a command of "ready, set, go" upon which they will be instructed to pinch as hard as possible for 3 seconds. Three trials will be completed with a 60 second rest period between trials, and the mean force will be calculated. |
| Secondary | Change in upper extremity (UE) sensation | Twice during each of the four testing & intervention sessions through study completion, an average of two weeks. | Sensation will be measured in the right UE using the Graded Redefined Assessment of Strength Sensibility and Prehension version 2 (GRASSP v2) sensation subtest. Semmes-Weinstein monofilaments ranging in size from 3.61 to 6.65 will be used in three locations on the palmar surface of the hand while the participant's vision is occluded with a blindfold. The smallest monofilament (3.61) will be tested 3 times per location with 2/3 accurate responses indicating intact sensation. If the participant cannot detect the 3.61 filament at all locations, testing will continue with the next heaviest filament until the participant detects a filament at all three test locations or until testing with the heaviest filament is complete. In contrast to the 3.61 filament, the three other filaments will be tested once per location. The total score will be calculated by summing the scores for each test location. The maximum score is 12 with higher scores denoting better UE sensation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Serial Reaction Time | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909317
GET https://conductscience.org/api/trials/v1/NCT07909317/registered